# A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients

> **NCT05729074** · PHASE1 · UNKNOWN · sponsor: **HK inno.N Corporation** · enrollment: 80 (estimated)

## Conditions studied

- Mild to Moderate Atopic Dermatitis

## Interventions

- **DRUG:** IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment
- **DRUG:** IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment
- **DRUG:** IN-A002 Ointment 1% or IN-A002 Placebo Ointment
- **DRUG:** IN-A002 Ointment 3% or IN-A002 Placebo Ointment
- **DRUG:** IN-A002 Ointment 5% or IN-A002 Placebo Ointment
- **DRUG:** IN-A002 Ointment 1%
- **DRUG:** IN-A002 Ointment 3%
- **DRUG:** Elidel Cream 1% (pimecrolimus)

## Key facts

- **NCT ID:** NCT05729074
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-13
- **Primary completion:** 2023-02-25
- **Final completion:** 2024-01-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05729074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05729074, "A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05729074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*